Your browser doesn't support javascript.
loading
An R848-Conjugated Influenza Virus Vaccine Elicits Robust Immunoglobulin G to Hemagglutinin Stem in a Newborn Nonhuman Primate Model.
Clemens, Elene A; Holbrook, Beth C; Kanekiyo, Masaru; Yewdell, Jonathan W; Graham, Barney S; Alexander-Miller, Martha A.
Afiliação
  • Clemens EA; Department of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
  • Holbrook BC; Department of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
  • Kanekiyo M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Yewdell JW; Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Graham BS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Alexander-Miller MA; Department of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
J Infect Dis ; 224(2): 351-359, 2021 07 15.
Article em En | MEDLINE | ID: mdl-33245745
ABSTRACT
Eliciting broadly protective antibodies is a critical goal for the development of more effective vaccines against influenza. Optimizing protection is of particular importance in newborns, who are highly vulnerable to severe disease following infection. An effective vaccination strategy for this population must surmount the challenges associated with the neonatal immune system as well as mitigate the inherent immune subdominance of conserved influenza virus epitopes, responses to which can provide broader protection. Here, we show that prime-boost vaccination with a TLR7/8 agonist (R848)-conjugated influenza A virus vaccine elicits antibody responses to the highly conserved hemagglutinin stem and promotes rapid induction of virus neutralizing stem-specific antibodies following viral challenge. These findings support the efficacy of R848 as an effective adjuvant for newborns and demonstrate its ability to enhance antibody responses to subdominant antigenic sites in this at-risk population.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Infecções por Orthomyxoviridae / Formação de Anticorpos Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: J Infect Dis Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Infecções por Orthomyxoviridae / Formação de Anticorpos Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: J Infect Dis Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos